Early Detection of Lung Cancer Using Low-Dose CT Scanning

University Hospitals

G. Rao, A. Gupta, L. Whalen

WCLC 2024 Insights: Optimal Management of Malignant Pleural Effusion

Insights from 2024 WCLC

P. Lee

Clinical Applications of ctDNA in Breast Cancer Diagnosis and Manage…

University of Miami Sylvester Comprehensive Cancer Center

D. Tripathy

Surveillance Imaging in Solid Tumors: More Complicated Than It Appea…

ecancer

C. Booth

HR+/HER2- Early Breast Cancer: Risk Assessment and Treatment Updates

University of Illinois Cancer Center

V. Gadi

The Evolving Role of Liquid Biopsy With a Focus on NSCLC, BC, and CRC

COR2ED The Heart of Medical Education

U. Malapelle

Development and Validation of RSClinN+ Tool for HR+/HER2- Node-Posit…

2024 ASCO® Annual Meeting Insights Hub

L. Pusztai

ESMO 2024 Insights: Real-World Evidence of Recurrence Risk in Node- …

2024 ESMO Annual Meeting Insights Hub

K. Jhaveri

TAILORx Trial: Endocrine Therapy, 21-Gene Recurrence Score, and Clin…

Sherry Yang

New Frontiers in Oncology: Advanced Diagnostics and Therapeutics

Springer Healthcare IME

S. Peters

Managing Metastatic Breast Cancer: Case Study Insights

Fred Hutch 14th Annual Comprehensive Hematology & Oncology Review Course

N. Hunter

Breast Imaging and the Young Patient

Cleveland Clinic Taussig Cancer Institute

L. Dean

HER2 Ultra-Low: Is It Real? A Close Look at Companion Diagnostics fo…

Yale Cancer Center

D. Rimm

Imaging for Neuroendocrine Neoplasms

North American Neuroendocrine Tumor Society

G. Spilberg

Biology and Clinical Relevance of ESR1 Mutation in Breast Cancer

Fred Hutchinson Cancer Center

N. Davidson

Inflammatory Breast Cancer - Diagnosis and Management Updates

Weill Cornell Medicine Oncology & Hematology

M. Cristofanilli

ASCO® 2024 Insights: "Elucidating the Immune Active State of HR+/HER…

2024 ASCO® Annual Meeting Insights Hub

E. Cobain

SABCS 2024 Summary: Addressing Pathologic and Therapeutic Challenges…

2024 SABCS Annual Meeting Insights Hub

L. Tabar

Young Women With HR+/HER2- Breast Cancer: Options for Risk Assessment

University of Colorado Cancer Center

V. Borges

ESMO 2024 Insights: Hypo vs. Normofractionated RT in eBC - 5-Year Re…

2024 ESMO Annual Meeting Insights Hub

S. Rivera